O. Merimsky et al., Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study, CANC CHEMOT, 45(2), 2000, pp. 177-181
Purpose: To assess the efficacy of gemcitabine in patients with a variety o
f sarcomas that have failed to respond or escaped Adriamycin- and ifosfamid
e-based chemotherapy. Patients and methods. A group of 18 symptomatic heavi
ly pretreated patients with sarcomas of bone or soft tissue received one in
duction course of gemcitabine at a dose of 1000 mg/m(2) per week for 7 cons
ecutive weeks, followed by 1 week rest. Response to the induction course wa
s assessed by interview and by repeated ancillary tests. If no progression
was observed, maintenance by gemcitabine 1000 mg/m(2) per week for 3 weeks
every 28 days was given until failure was clinically or radiologically evid
ent. Results: A total of 51 cycles of gemcitabine were given including 18 c
ycles of induction. A mean of 3.6 postinductron cycles were given to nine p
atients. The treatment was well tolerated by the patients. One partial resp
onse (leiomyosarcoma) and one minimal response (angiosarcoma) were observed
, yielding a true objective response rate of 5.5%. An additional six patien
ts achieved stabilization of disease (chondrosarcoma and osteosarcoma), yie
lding an overall progression-free rate of 44%. The median time to progressi
on was more than 27 weeks. Clinical benefit response was observed only in t
hose who also achieved a progression-free state. Conclusion: Gemcitabine wa
s found to be effective in achieving stabilization and even a minimal respo
nse of soft tissue or bone sarcoma refractory to standard chemotherapy.